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SI/CTR Abstract
DOWN REGULATION WITH LUTEAL GnRH AGONIST THERAPY IN EUPLOID EMBRYO
TRANSFERS DOES NOT IMPACT PREGNANCY RATES
Isabelle Levin BA, Keri Bergin MD, Dmitry Gounko BS, Joseph Lee BA*, Alan Copperman MD

Introduction: Gonadotropin-releasing hormone (GnRH) agonists have been used during
assisted reproductive technology (ART) treatment for pituitary suppression and stimulation.
Currently, clinical opinion is divided about whether GnRH agonist therapy improves pregnancy
rates when used for luteal down-regulation in a frozen euploid embryo transfer (FET). This study
evaluated the clinical utility of GnRH agonist down-regulation in single, euploid FET cycles.
Methods: A retrospective analysis was performed, using data from patients who underwent a
single, euploid FET cycle from 2012 to 2019. Patients were segregated into two cohorts: Group
A: single, euploid FET with down-regulation using GnRH agonist; Group B: single, euploid FET
without down-regulation using GnRH agonist. Primary outcomes include pregnancy rates
among cohorts.
Results: Group A demonstrated a pregnancy rate of 72.92% in 96 cycles. Group B
demonstrated a pregnancy rate of 73.27% in 5,668 cycles. There was no difference in
pregnancy rates between groups, X2(2, N = 5764) = .0061, p = .94. A subgroup of patients
(n=5) with endometriosis in Group A achieved an 80% (4/5) pregnancy rate.
Discussion: Single, euploid FET cycle pregnancy rates were not affected by the use of
down-regulation with a GnRH agonist. Increased pregnancy rates found with prolonged GnRH
agonist use in other studies weren’t seen with short term use for FET cycles. Future research
should focus on molecular markers and gene transcription signatures to attempt to define
whether there is an ideal population of patients who would benefit from GnRH agonist
down-regulation prior to FET.

